Cellectis (NASDAQ:CLLS) Share Price Crosses Above 50-Day Moving Average – What’s Next?

Cellectis S.A. (NASDAQ:CLLS)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.17 and traded as high as $4.46. Cellectis shares last traded at $4.37, with a volume of 406,309 shares changing hands.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Cellectis to a “hold” rating in a research note on Saturday, September 20th. Wells Fargo & Company restated a “positive” rating and issued a $4.00 price target on shares of Cellectis in a research report on Monday, October 20th. Barclays boosted their price objective on shares of Cellectis from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.00.

Cellectis Stock Up 5.0%

The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.63. The company’s 50-day simple moving average is $4.17 and its 200 day simple moving average is $3.05.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Friday, November 7th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%. The company had revenue of $37.16 million during the quarter, compared to analysts’ expectations of $8.22 million. Analysts predict that Cellectis S.A. will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Several hedge funds and other institutional investors have recently modified their holdings of the stock. OLD Mission Capital LLC acquired a new stake in Cellectis in the 1st quarter worth approximately $31,000. Acadian Asset Management LLC grew its stake in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the last quarter. Delaney Dennis R purchased a new stake in Cellectis in the third quarter valued at approximately $68,000. Virtu Financial LLC purchased a new position in Cellectis during the 3rd quarter worth approximately $72,000. Finally, Millennium Management LLC lifted its stake in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the period. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.